

What is Claimed:

1. A method of treating a disease, disorder or condition in a subject comprising administering to the subject a population of exosomes or a composition comprising a population of exosomes, wherein said population of exosomes is positive for CD1c, CD20, CD24, CD25, CD29, CD2, CD3, CD8, CD9, CD11c, CD14, CD19, CD31, CD40, CD41b, CD42a, CD44, CD45, CD49e, CD4, CD56, CD62P, CD63, CD69, CD81, CD86, CD105, CD133-1, CD142, CD146, CD209, CD326, HLA-ABC, HLA-DRDPDQ, MCSP, ROR1, SSEA-4, or combinations thereof.
2. The method of claim 1, wherein said population of exosomes is positive for CD1c, CD20, CD24, CD25, CD29, CD2, CD3, CD8, CD9, CD11c, CD14, CD19, CD31, CD40, CD41b, CD42a, CD44, CD45, CD49e, CD4, CD56, CD62P, CD63, CD69, CD81, CD86, CD105, CD133-1, CD142, CD146, CD209, CD326, HLA-ABC, HLA-DRDPDQ, MCSP, ROR1, and SSEA-4.
3. The method of claim 1, wherein said population of exosomes is positive for CD9, CD29, CD42a, CD62P, CD63, CD81, CD133-1, CD146, HLA-DRP, or combinations thereof.
4. The method of claim 3, wherein said population of exosomes is positive for CD9, CD29, CD42a, CD62P, CD63, CD81, CD133-1, CD146, and HLA-DRP.
5. The method of claim 1, wherein said population of exosomes is positive for 2, 3, 4, 5, 6, 7, 8, 9, 10, or more markers selected from the group consisting of CD1c, CD20, CD24, CD25, CD29, CD2, CD3, CD8, CD9, CD11c, CD14, CD19, CD31, CD40, CD41b, CD42a, CD44, CD45, CD49e, CD4, CD56, CD62P, CD63, CD69, CD81, CD86, CD105, CD133-1, CD142, CD146, CD209, CD326, HLA-ABC, HLA-DRDPDQ, MCSP, ROR1, and SSEA-4.
6. The method of claim 3, wherein said population of exosomes is positive for 2, 3, 4, 5, 6, 7, 8, 9, 10, or more markers selected from the group consisting of CD9, CD29, CD42a, CD62P, CD63, CD81, CD133-1, CD146, and HLA-DRP.

7. The method of any one of claims 1-6, wherein said population of exosomes is CD3-, CD11b-, CD14-, CD19-, CD33-, CD192-, HLA-A-, HLA-B-, HLA-C-, HLA-DR-, CD11c- or CD34-.
8. The method of any one of claims 1-6, wherein said population of exosomes is CD3-, CD11b-, CD14-, CD19-, CD33-, CD192-, HLA-A-, HLA-B-, HLA-C-, HLA-DR-, CD11c- and CD34-.
9. The method of any one of claims 1-8, wherein said population of exosomes comprise non-coding RNA molecules.
10. The method of claim 9, wherein said non-coding RNA molecules are microRNAs.
11. The method of claim 10, wherein said microRNAs are selected from the group consisting of the microRNAs in Table 7, and combinations thereof.
12. The method of claim 10, wherein said microRNAs are selected from the group consisting of hsa-mir-26b, hsa-miR-26b-5p, hsa-mir-26a-2, hsa-mir-26a-1, hsa-miR-26a-5p, hsa-mir-30d, hsa-miR-30d-5p, hsa-mir-100, hsa-miR-100-5p, hsa-mir-21, hsa-miR-21-5p, hsa-mir-22, hsa-miR-22-3p, hsa-mir-99b, hsa-miR-99b-5p, hsa-mir-181a-2, hsa-mir-181a-1, hsa-miR-181a-5p, and combinations thereof.
13. The method of any one of claims 1-12, wherein said population of exosomes comprise a cytokine selected from the group consisting of the cytokines in Table 3 or Table 11, and combinations thereof.
14. The method of any one of claims 1-13, wherein said population of exosomes comprise a cytokine receptor in Table 4, and combinations thereof.
15. The method of any one of claims 1-14, wherein said population of exosomes comprise a protein selected from the group consisting of the proteins in Table 6, and combinations thereof.

16. The method of any one of claims 1-14, wherein said population of exosomes comprise a protein selected from the group consisting of Cytoplasmic aconitate hydratase, Cell surface glycoprotein MUC18, Protein arginine N-methyltransferase 1, Guanine nucleotide-binding protein G(s) subunit alpha, Cullin-5, Calcium-binding protein 39, Glucosidase 2 subunit beta, Chloride intracellular channel protein 5, Semaphorin-3B, 60S ribosomal protein L22, Spliceosome RNA helicase DDX39B, Transcriptional activator protein Pur-alpha, Programmed cell death protein 10, BRO1 domain-containing protein BROX, Kynurenine--oxoglutarate transaminase 3, Laminin subunit alpha-5, ATP-binding cassette sub-family E member 1, Syntaxin-binding protein 3, Proteasome subunit beta type-7, and combinations thereof.
17. The method of any one of claims 1-16, wherein said population of exosomes is a placental-derived population of exosomes.
18. The method of claim 17, wherein said placental-derived population of exosomes is derived from a media of a whole placenta culture.
19. The method of claim 17, wherein said placental-derived population of exosomes is derived from a media of a culture comprising placental lobes or portions of a placenta.
20. The method of claim 17, wherein said placental-derived population of exosomes is derived from a media of a culture comprising placental stem cells, preferably placental-derived adherent cells (PDAC).
21. The method of any one of claims 18-20, wherein the media is selected from the group consisting of a tissue culture media, a saline solution, and a buffered saline solution.
22. The method of any one of claims 1-21, wherein said population of exosomes comprise at least one marker molecule at a level at least two-fold higher than a population of exosomes derived from mesenchymal stem cells, cord blood, or placental perfusate.

23. The method of any one of claims 1-22, wherein said population of exosomes comprise at least one marker molecule at a level at least two-fold lower than a population of exosomes derived from mesenchymal stem cells, cord blood, or placental perfusate.
24. The method of any one of claims 1-23, wherein the disease, disorder or condition is a lung disease disorder or condition.
25. The method of claim 24, wherein the lung disease disorder or condition is selected from the group consisting of acute lung injury, acute and chronic diseases, asthma, chronic obstructive pulmonary disease (COPD), lung fibrosis, idiopathic pulmonary fibrosis, recovery of lung surgery after lung cancer, pulmonary embolism, acute respiratory distress syndrome, pneumonia, viral infection, coronavirus infection, Covid-19, and ventilator induced lung injury.
26. The method of any one of claims 1-23, wherein the disease, disorder or condition is a liver disease disorder or condition.
27. The method of claim 26, wherein the liver disease disorder or condition is selected from the group consisting of acute liver injury, acute and chronic diseases, liver cirrhosis, liver fibrosis, liver inflammation, metabolic disorders, liver damages caused by drugs, poisons, alcohol, virus (e.g., hepatitis) or other infectious disease, and cholestatic liver diseases.
28. The method of any one of claims 1-23, wherein the disease, disorder or condition is a brain / spinal cord disease disorder or condition.
29. The method of claim 28, wherein the brain / spinal cord disease disorder or condition is selected from the group consisting of acute brain / spinal cord injury, acute and chronic diseases, stroke, transient ischemic attack, Parkinson's and other movement disorders, dementias, Alzheimer's diseases epilepsy / seizures, myelopathy, multiple sclerosis, infections of the central nervous system, spinal cord trauma, spinal cord inflammation, amyotrophic lateral sclerosis, spinal muscular atrophy.

30. The method of any one of claims 1-23, wherein the disease, disorder or condition is a kidney disease disorder or condition.
31. The method of claim 30, wherein the kidney disease disorder or condition is selected from the group consisting of acute kidney injury, acute and chronic diseases, kidney injury or damage induced by trauma, drugs (e.g., chemotherapeutic agents), kidney cysts, kidney stones, and kidney infections, recovery of kidney function after kidney transplant, diabetic nephropathy, and polycystic kidney disease.
32. The method of any one of claims 1-23, wherein the disease, disorder or condition is a gastrointestinal disease disorder or condition.
33. The method of claim 32, wherein the gastrointestinal disease disorder or condition is selected from the group consisting of acute gastrointestinal injury, autoimmune disease, acute and chronic diseases, Crohn's disease, irritable bowel syndrome, perianal abscesses, colitis, colon polyps and cancer.
34. The method of any one of claims 1-23, wherein the disease, disorder or condition is a bone marrow disease disorder or condition.
35. The method of claim 32, wherein the bone marrow disease disorder or condition is selected from the group consisting of acute and chronic diseases, anemia, leukopenia, thrombocytopenia aplastic anemia, myeloproliferative disorders, and stem cell transplantation.
36. The method of any one of claims 1-23, wherein the disease, disorder or condition is an eye disease disorder or condition.
37. The method of claim 36, wherein the eye disease disorder or condition is selected from the group consisting of acute eye injury, chronic and acute eye diseases, dry-eye syndrome and diabetic retinopathy, and macular degeneration.
38. The method of any one of claims 1-23, wherein the disease, disorder or condition is a spleen disease disorder or condition.

39. The method of claim 38, wherein the spleen disease disorder or condition is selected from the group consisting of acute spleen injury, chronic and acute spleen diseases, diseases associated with enlarged or de-regulated spleen functions, and lupus.
40. The method of any one of claims 1-23, wherein the disease, disorder or condition is a skin disease disorder or condition.
41. The method of claim 40, wherein the skin disease disorder or condition is selected from the group consisting of acute skin injury, chronic and acute skin diseases, diabetic foot ulcer, wound due to chemical burn, fire burn, skin or tissue damage caused, e.g., by injury, disease or surgical procedures, hair loss, a hair follicle disease, disorder or condition, wrinkles, and reduced firmness.
42. The method of any one of claims 1-23, wherein the disease, disorder or condition is an ischemic disease disorder or condition.
43. The method of claim 42, wherein the ischemic disease disorder or condition is selected from the group consisting of acute ischemic injury, chronic and acute ischemic diseases, ischemic heart disease, ischemic vascular disease, ischemic colitis, mesenteric ischemia, Brain ischemia (e.g., stroke), acute or chronic limb ischemia, cutaneous ischemia, ischemic kidney, and the promotion of angiogenesis in tissues or organs in need thereof.
44. The method of any one of claims 1-23, wherein the disease, disorder or condition is a heart / cardiovascular disease disorder or condition.
45. The method of claim 44, wherein the heart / cardiovascular disease disorder or condition is selected from the group consisting of acute heart / cardiovascular injury, hypertension, atherosclerosis, myocardial infarction (MI), and chronic heart failure.
46. The method of any one of claims 1-23, wherein the disease, disorder or condition is an aging associated disease disorder or condition.

47. The method of claim 42, wherein the ageing associated disease disorder or condition is selected from the group consisting of age related fragility, age related diabetics, Alzheimer's diseases; age related macular degeneration, age related hearing loss, age related memory loss, age related cognitive decline, age related dementia, age related nuclear cataract, age associated loss of function and other effects of ageing.
48. The method of any one of claims 1-23, wherein the disease, disorder or condition is a systemic disease disorder or condition.
49. The method of claim 48, wherein the systemic disease disorder or condition is selected from the group consisting of acute and chronic diseases, graft versus host disease, and infections (e.g., ear infection).
50. The method of any one of claims 1-49, wherein the composition is formulated for intravenous administration.
51. The method of any one of claims 1-49, wherein the composition is formulated for local injection.
52. The method of any one of claims 1-49, wherein the composition is formulated for topical administration.
53. The method of any one of claims 1-49, wherein the composition is formulated for inhalation.
54. The method of any one of claims 1-49, wherein the composition is formulated for oral administration.
55. The method of any one of claims 1-49, wherein the composition is formulated for subcutaneous administration.
56. The method of any one of claims 1-49, wherein the composition is formulated for buccal or sublingual administration.

- 57. The method of any one of claims 1-49, wherein the composition is formulated for administration to the ear.
- 58. The method of any one of claims 1-49, wherein the composition is formulated for nasal administration.
- 59. The method of any one of claims 1-49, wherein the composition is formulated for ocular administration.
- 60. The method of any one of claims 1-59, wherein the subject is a human.